Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1461-1470

  Winters, Nicholas ^a,b   Butler Laporte, Guillaume ^a   Menzies, Dick ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; IMIPENEM; MACROLIDE; MEROPENEM; TERIZIDONE; THIORIDAZINE; TUBERCULOSTATIC AGENT; AMOXICILLIN; AZITHROMYCIN; CILASTATIN; CLAVULANIC ACID; ISOXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; THIENAMYCIN DERIVATIVE;

ADULT; ATTRIBUTABLE RISK; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS, MULTIDRUG-RESISTANT;

AMOXICILLIN; ANTITUBERCULAR AGENTS; AZITHROMYCIN; CILASTATIN; CLARITHROMYCIN; CLAVULANIC ACID; HIV INFECTIONS; HUMANS; IMIPENEM; ISOXAZOLES; MACROLIDES; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIENAMYCINS; THIORIDAZINE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84946542230     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00649-2015     Document Type: Review

References (97)

1. World Health Organization. Global Tuberculosis Report 2014. Geneva, World Health Organization, 2014.
2. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
3. World Health Organization. Extensively Drug-resistant Tuberculosis (XDR-TB): Recommendations for Prevention and Control. Geneva, World Health Organization, 2006.
4. Marks SM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis 2014; 20: 812-821.
5. Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health 2014; 7: 75-91.
6. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012; 9: e1001300.
7. World Health Organization. Treatment of Tuberculosis Guidelines. 4th Edn. Geneva, World Health Organization, 2010.
8. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
9. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
10. Chang KC, Yew WW, Tam CM, et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-4104.
11. Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68: 284-293.
12. Hwang TJ, Wares DF, Jafarov A, et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 2013; 17: 1257-1266.
13. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
15. Hwang TJ, Wares DF, Jafarov A, et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 2013; 17: 1257-1266.
16. Anderson LF, Tamne S, Watson JP, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 2013; 18: 20601.
17. Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2000; 181: 1289-1297.
18. Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: 1234-1243.
19. Böszörményi M. Dreifach-Blindversuch zum Vergleich der Nebenwirkungen von Terizidon (Terivalidin) und Cycloserin [Triple placebo test for comparison of side effects of terizidone (terivalidin) and cycloserine]. Int J Clin Pharmacol 1973; 8: 37-41.
20. Briones FH. Avaliacao das manifestacoes secundarias em doentes tratados com terizidona [Evaluation of secondary manifestations in patients treated with terizidone]. Rev Bras Med 1970; 27: 271-275.
21. Brown BA, Griffith DE, Girard W, et al. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis 1997; 24: 958-964.
22. Burman WJ, Reves RR, Rietmeijer CA, et al. A retrospective comparison of clarithromycin versus rifampin in combination treatment for disseminated Mycobacterium avium complex disease in AIDS: clarithromycin decreases transfusion requirements. Int J Tuberc Lung Dis 1997; 1: 163-169.
23. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905-911.
24. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-317.
25. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
26. Cohn DL, Fisher EJ, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Clin Infect Dis 1999; 29: 125-133.
27. Cox HS, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2007; 2: e1126.
28. + cell count: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 133: 493-503.
29. Dautzenberg B, Saint Marc T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993; 153: 368-372.
30. Dautzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995; 107: 1035-1040.
31. Dautzenberg B, Truffot-Pernot C, Hazebroucq J, et al. A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. Infection 1997; 25: 16-21.
32. Davies BS, Roberts CH, Kaul S, et al. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. Scand J Infect Dis 2012; 44: 815-819.
33. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
34. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
35. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
36. Dubé MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis 1997; 176: 1225-1232.
37. Dumon JF, Aimone J, Dumon G. Note preliminaire sur la terizidone [Preliminary note on terizidone]. Mars Med 1972; 109: 730-732.
38. Dunne M, Fessel J, Kumar P, et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1245-1252.
39. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000; 342: 1085-1092.
40. Ferrara G, Richeldi L, Bugiani M, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9: 507-513.
41. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003; 124: 1482-1486.
42. Fournier S, Burguière AM, Flahault A, et al. Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. Eur J Clin Microbiol Infect Dis 1999; 18: 16-22.
43. Friedman ND, Athan E, Hughes AJ, et al. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Negl Trop Dis 2013; 7: e2315.
44. Fujita M, Kajiki A, Tao Y, et al. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. J Infect Chemother 2012; 18: 146-151.
45. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999; 28: 1080-1085.
46. Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000; 30: 288-292.
47. Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001; 32: 1547-1553.
48. Griffith DE, Brown BA, Girard WM, et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 983-989.
49. Griffith DE, Brown BA, Girard WM, et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995; 21: 594-598.
50. Hammerli A, Gallindo IS. Tratamento da tuberculose cronica resistente. Um novo tuberculostatico: terizidona. [Treatment of resistant chronic tuberculosis. A new antitubercular agent: terizidone.] Rev Bras Med 1969; 26: 684-688.
51. Hasegawa N, Nishimura T, Ohtani S, et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009; 136: 1569-1575.
52. Havlir DV, Dubé MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335: 392-398.
53. Hughes WT, Dankner WM, Yogev R, et al. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis 2005; 40: 136-145.
54. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One 2012; 7: e40781.
55. Jenkins PA, Campbell IA, Banks J, et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63: 627-634.
56. Jeon DS, Kim DH, Kang HS, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 594-600.
57. Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896-902.
58. Jiang RH, Xu HB, Li L. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. Int J Antimicrob Agents 2013; 42: 36-41.
59. Kim EY, Chi SY, Oh IJ, et al. Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease. Korean J Intern Med 2011; 26: 54-59.
60. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
61. Kobashi Y, Abe M, Mouri K, et al. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 2012; 18: 436-443.
62. Kobashi Y, Matsushima T. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease. Intern Med 2003; 42: 670-675.
63. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007; 101: 130-138.
64. Koletar SL, Berry AJ, Cynamon MH, et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrob Agents Chemother 1999; 43: 2869-2872.
65. Kvasnovsky CL, Cegielski JP, Erasmus R, et al. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr 2011; 57: 146-152.
66. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 584-593.
67. Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, et al. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44: 1057-1064.
68. Lyu J, Jang HJ, Song JW, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011; 105: 781-787.
69. May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. Clin Infect Dis 1997; 25: 621-629.
70. Micheletti V, Teti V, Fenzi P, et al. [The therapy of pulmonary tuberculosis in psychopathic patients, using terizidone]. Minerva Med 1968; 59: 2459-2465.
71. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
72. Miwa S, Shirai M, Toyoshima M, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease: a preliminary study. Ann Am Thorac Soc 2014; 11: 23-29.
73. Gonzalez Montaner LJ, Dambrosi A, Manassero M, et al. Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle 1982; 63: 291-294.
74. Murray MP, Laurenson IF, Hill AT. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Clin Infect Dis 2008; 47: 222-224.
75. O'Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 2012; 6: e1473.
76. O'Donnell MR, Padayatchi N, Kvasnovsky C, et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013; 19: 416-424.
77. Oldfield EC III, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1998; 26: 611-619.
78. Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009; 48: 1413-1419.
79. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-391.
80. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383: 1230-1239.
81. Rizzo A, Gomes A, Antunes G, et al. Cicloserina e terizidona no tratamento da tuberculose pulmonar: estudo clinico da tolerancia [Cycloserine and terizidone in the treatment of pulmonary tuberculosis: clinical study of tolerance]. Rev Bras Med 1969; 26: 119-122.
82. Roussel G, Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. Int J Tuberc Lung Dis 1998; 2: 462-470.
83. Seddon JA, Hesseling AC, Godfrey-Faussett P, et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 2014; 69: 458-464.
84. Seddon JA, Hesseling AC, Willemse M, et al. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54: 157-166.
85. Seung KJ, Becerra MC, Atwood SS, et al. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect 2014; 20: 441-446.
86. Shafran I, Kugler L, El-Zaatari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34: 22-28.
87. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377-383.
88. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
89. Shmelev NA, Shabalova LN, Kolosovskaia VP. Sravnitel'noe kliniko-elektorentsefalograficheskoe izuchenie perenosimosti tsikloserina i terizidona [Comparative clinical electroencephalographic study of cycloserine and terizidone tolerance]. Antibiotiki 1975; 20: 174-180.
90. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.
91. Tahaoglu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
92. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160: 866-872.
93. Törün T, Güngör G, Ozmen J, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377.
94. Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153: 1766-1772.
95. Ward TT, Rimland D, Kauffman C, et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 27: 1278-1285.
96. Xu HB, Jiang RH, Xiao HP. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect 2012; 18: 1104-1110.
97. Zrilic V, Mijatovic M, Mirkovic S, et al. Rezultati klinickog ispitivanja novog antituberkulotika terizidona (Terivalidina) [Results of clinical trials of a new antitubercular agent, terizidone (Terivalidine)]. Plucne Bolesti Tuberk 1972; 24: 89-98.